PRESS RELEASES
SANOFI AT A GLANCE

Press releases

September 16, 2022
Press releases
Media Update: CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved treatment for hemolytic anemia in adult patients with cold agglutinin disease
September 16, 2022
Press releases
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
September 16, 2022
Press releases
Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in The Lancet
September 8, 2022
Press releases
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
September 6, 2022
Press releases
Media Update: New Dupixent® (dupilumab) data at EADV 2022 adds to body of evidence across multiple inflammatory skin diseases
ALL PRESS RELEASES

Contact the Media team

Global Media Relations Department
54 rue La Boétie
75008 Paris FRANCE
+33 (0)1 53 77 46 46 • mr@sanofi.com

ALL THE CONTACTS

You are a journalist and have a question about Sanofi, please contact the Global Media Relations team: please note the contact details are only for Medias. For any other request, please call the switchboard: +33 1 53 77 40 00

Email Alerts

Social feed

Resources

Sanofi at a glance

Publications

Our Integrated Report 2021

Annual Report on Form 20-F 2021

Half Year 2022 Financial Report

ALL THE PUBLICATIONS

Press Statements

Find out more about all our press statements